The global market for Fluorescein Angiography was estimated at US$829.5 Million in 2024 and is projected to reach US$1.3 Billion by 2030, growing at a CAGR of 7.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Fluorescein Angiography market.
Segments: Type (Traditional Fluorescein Angiography, Confocal Scanning Laser Ophthalmoscopy); Application (Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis & Retinal Vasculitis, Choroidal Tumors, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Others)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Fluorescein Angiography Market - Key Trends & Drivers Summarized
Why Is Fluorescein Angiography Gaining Importance in Ophthalmology?
Fluorescein angiography (FA) is a vital diagnostic imaging technique used to assess blood flow in the retina and choroid, aiding in the early detection and management of eye disorders such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusions. The rising prevalence of diabetes and an aging global population are fueling demand for advanced retinal imaging solutions. Additionally, improvements in teleophthalmology and AI-powered image analysis are enhancing the accessibility and accuracy of FA procedures. As the burden of vision-related diseases grows, healthcare providers are increasingly relying on fluorescein angiography for accurate diagnosis and treatment planning.What Technological Advancements Are Improving Fluorescein Angiography?
Advancements in high-speed digital imaging, AI-driven diagnostic tools, and ultra-widefield angiography are transforming FA technology. AI-powered image analysis software is improving early disease detection by automatically identifying abnormal vascular patterns and leakages. The development of non-invasive and contrast-free angiography techniques, such as optical coherence tomography angiography (OCTA), is reducing patient discomfort while maintaining diagnostic accuracy. Additionally, innovations in hyperspectral imaging are enabling more detailed visualization of retinal microcirculation. The integration of cloud-based ophthalmic imaging platforms is also improving collaboration between specialists, facilitating remote diagnosis and second-opinion consultations.How Are Regulations and Market Trends Influencing Fluorescein Angiography?
Regulatory agencies such as the FDA, EMA, and WHO enforce strict guidelines for contrast agents used in FA procedures, ensuring patient safety and imaging quality. The shift toward non-invasive diagnostic methods is driving research into alternative angiography techniques with fewer side effects. Additionally, the expansion of AI-assisted ophthalmology is influencing market trends, allowing for faster and more precise diagnostic workflows. The rising demand for portable and home-based retinal imaging solutions is also encouraging the development of compact FA devices. As ophthalmic imaging technology evolves, fluorescein angiography is becoming more patient-friendly and diagnostically efficient.What’s Driving the Future Growth of the Fluorescein Angiography Market?
The future of FA is being shaped by AI-powered predictive diagnostics, next-generation imaging contrast agents, and the integration of telemedicine in ophthalmology. The rise of personalized medicine and targeted therapies will drive demand for more precise retinal imaging techniques. The increasing use of AI-assisted decision-making tools will further improve diagnostic accuracy and workflow efficiency. Additionally, the development of non-invasive, label-free imaging technologies will reduce reliance on dye-based angiography, minimizing patient risks. As vision care continues to advance, FA will remain a cornerstone of ophthalmic diagnostics, supporting early disease detection and improved patient outcomes.Report Scope
The report analyzes the Fluorescein Angiography market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Type (Traditional Fluorescein Angiography, Confocal Scanning Laser Ophthalmoscopy); Application (Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis & Retinal Vasculitis, Choroidal Tumors, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Others)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Traditional Fluorescein Angiography segment, which is expected to reach US$922.8 Million by 2030 with a CAGR of a 8.8%. The Confocal Scanning Laser Ophthalmoscopy segment is also set to grow at 5.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $226.0 Million in 2024, and China, forecasted to grow at an impressive 12.2% CAGR to reach $277.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Fluorescein Angiography Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Fluorescein Angiography Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Fluorescein Angiography Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Alcon Laboratories, Inc., Bayer AG, Canon Inc., Carl Zeiss Meditec AG, CenterVue SpA and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 34 Featured):
- Alcon Laboratories, Inc.
- Bayer AG
- Canon Inc.
- Carl Zeiss Meditec AG
- CenterVue SpA
- Chongqing Vision Star Optical Co., Ltd.
- Clarity Medical Systems, Inc.
- Eyenuk, Inc.
- Eye-Tech
- Forus Health Pvt Ltd.
- FOSHAN CONCERN MEDICAL EQUIPMENT CO.,LTD.
- Guangzhou Happycare Medical Equipment
- Heidelberg Engineering GmbH
- Imagine Eyes
- Johnson & Johnson Vision Care, Inc.
- Kowa Company Ltd.
- Marco Ophthalmic, Inc.
- NIDEK Co., Ltd.
- Novartis AG
- Optomed Oy (Ltd.)
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alcon Laboratories, Inc.
- Bayer AG
- Canon Inc.
- Carl Zeiss Meditec AG
- CenterVue SpA
- Chongqing Vision Star Optical Co., Ltd.
- Clarity Medical Systems, Inc.
- Eyenuk, Inc.
- Eye-Tech
- Forus Health Pvt Ltd.
- FOSHAN CONCERN MEDICAL EQUIPMENT CO.,LTD.
- Guangzhou Happycare Medical Equipment
- Heidelberg Engineering GmbH
- Imagine Eyes
- Johnson & Johnson Vision Care, Inc.
- Kowa Company Ltd.
- Marco Ophthalmic, Inc.
- NIDEK Co., Ltd.
- Novartis AG
- Optomed Oy (Ltd.)
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 76 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 829.5 Million |
Forecasted Market Value ( USD | $ 1300 Million |
Compound Annual Growth Rate | 7.7% |
Regions Covered | Global |